Infection with high-risk human papillomaviruses (HPV) can lead to the development of cervical cancer. This process depends on the interaction of the virus-encoded oncoproteins, E6 and E7, with a variety of host regulatory proteins. As E7 shares both functional and structural similarities with the Adenovirus E1a (Ad E1a) protein, we were interested in investigating the possible interactions between E7 and the transcriptional coactivator p300, since it was originally identified as a target of Ad E1a. Using a variety of assays, we show that E7s from both high-and low-risk HPV types interact with p300. Mutational analysis of E7 maps the site of the interaction to a region spanning the pRb-binding domain and the CKII phosphorylation site. We also map the site of interaction on p300 largely to the CH1 domain. In addition, we demonstrate that the binding between 16E7 and p300 is direct, and can be detected in vivo by coimmunoprecipitation and mammalian two-hybrid assays. Finally, we show that E7 can abolish the p300-mediated E2 transactivation function, suggesting that complex formation between E7 and p300 may contribute to the regulation of E2 transcriptional activity.
Introduction
Small DNA viruses such as HPV, SV40 and Polyoma rely on the host cell machinery in order to replicate their genomes. Since these viruses normally infect resting or differentiated cells, they have evolved various strategies to stimulate unscheduled host cell DNA synthesis. HPV exerts its transforming function through its two major oncoproteins, E6 and E7 (Pim et al., 2001 for review). A causal role for these two proteins in the development of cervical cancer is supported by observations that they are both retained and expressed in cervical tumours, and in cell lines derived from them (Schwarz et al., 1985; Androphy et al., 1987; Banks et al., 1987) . Both oncoproteins manipulate programmed cell growth and proliferation through their physical and functional interaction with several master cell cycle regulators.
One of the first described interactions for the high-risk E6 oncoprotein was with the p53 tumour suppressor . In complex with the ubiquitin ligase, E6AP, the high-risk HPV E6 proteins target p53 for ubiquitin-mediated degradation (Scheffner et al., 1990; Huibregtse et al., 1991) , thereby abrogating p53 functions in cell cycle control and apoptosis. More recently, many additional E6 targets have been described (Mantovani and Banks 2001 for review), including the p300/CBP transcriptional coactivators (Patel et al., 1999; Zimmermann et al., 1999 Zimmermann et al., , 2000 Bernat et al., 2002) . HPV E6 also cooperates with the viral E7 protein in the immortalization of primary human keratinocytes (Barbosa and Schlegel, 1989; Hawley-Nelson et al., 1989; Mu¨nger et al., 1989) , the natural host cells of the virus in vivo. HPV E7 proteins interact with the so-called 'pocket proteins' including the retinoblastoma protein pRb, p107 and p130 (Dyson et al., 1989 (Dyson et al., , 1992 Davies et al., 1993) , which are negative cell-cycle regulators involved in the G1/S and G2/M transition. The interaction between high-risk E7 and pRb results in its enhanced phosphorylation and degradation . pRb destruction leads to the release of the E2F family of transcription factors and the subsequent activation of genes promoting cell proliferation (Nevins, 2001 ) for review). However, the stimulatory effect of E7 upon cell proliferation does not only depend on its association with pRb, since E7 targets the function of a plethora of cell cycle regulators including cyclin E (McIntyre et al., 1996) and the cyclin/CDK inhibitor p21 WAF/Cip1 (Funk et al., 1997; Jones et al., 1997) , together with the metabolic regulators acid-alpha glucosidase (Zwerschke et al., 2000) and M2 pyruvate kinase (Zwerschke et al., 1999) . HPV E7 also interferes with the activity of a variety of cellular transcription factors such as AP-1 (Antinore et al., 1996) , interferon regulatory factor-1 (Park et al., 2000) , forkhead transcription factor MPP2 (Luscher-Firzlaff et al., 1999) and the TATA-boxbinding protein (Massimi et al., 1996) , as well as with Mi2 and histone deacetylase activity (Brehm et al., 1999) . This multiplicity of interaction partners allows a highly complex and sophisticated manipulation of cell-cycle progression and proliferation (Mu¨nger et al., 2001, for review) .
CBP and p300 were originally identified as targets of CREB and Ad E1a, respectively (Chrivia et al., 1993; Eckner et al., 1994) . Both proteins participate in basic cellular functions including DNA repair, cell growth, differentiation and apoptosis. They coordinate a variety of transcriptional pathways, acting both as transcriptional activators and repressors, integrating multiple signal-dependent transcriptional events (Goodman and Smolik, 2000 for review) . The transcriptional regulating properties of p300 appear to be exercised through multiple mechanisms. It acts as a protein bridge connecting different transcription factors to the basic transcriptional apparatus, thus providing a scaffold for the assembly of multicomponent transcription coactivator complexes. Another key property of p300 is the presence of histone acetyltransferase (HAT) activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) , which endows p300 with the capacity to influence chromatin structure by modulating nucleosomal histones. Moreover, p300/CBP has been shown to acetylate key transcription factors such as p53 and pRb (Gu and Roeder, 1997; Chan et al., 2001) , thereby using acetylation as another means of regulating protein function.
Genetic experiments have demonstrated essential roles for p300/CBP in normal embryonic development (Yao et al., 1998; Tanaka et al., 2000) . Mutations in p300 have also been found in many types of tumours (Gayther et al., 2000) , and mutation of human CBP causes Rubinstein-Taybi syndrome (RTS), which leads to an increased risk of cancer (Giles et al., 1998) . The human genetic data were further substantiated by experiments using knockout mice, which display an increased susceptibility to tumours of haematopoietic origin (Kung et al., 2000) . The role of p300/CBP in human disease, coupled with the biochemical evidence, suggests that CBP and p300 are tumour-suppressor proteins with essential roles in cell-cycle control, cellular differentiation and development.
Many viral oncoproteins have been found to modulate p300/CBP function, further emphasizing the central importance of p300/CBP in maintaining cellular homeostasis. These include Ad E1a, SV40 LT, HPV E6, EBV EBNA2, HTLV Tax and HIV Tat (Eckner et al., 1994 (Eckner et al., , 1996 Hottiger and Nabel, 1998; Yan et al., 1998; Patel et al., 1999; Zimmermann et al., 1999 Zimmermann et al., , 2000 Wang et al., 2000; Scoggin et al., 2001; Bernat et al., 2002) . In the case of E1a, binding to p300 was found to be essential for the oncogenic and growth-stimulatory activities of E1a, and for its ability to repress several tissue-specific transcriptional control elements (Jelsma et al., 1989; Peeper and Zantema, 1993) . Recent studies have also shown that HPV E7 can repress transcription by a variety of different mechanisms. Since HPV E7 shares structural and functional homology with the Ad E1a protein (Phelps et al., 1988; Storey et al., 1988) , we initiated a series of studies to investigate whether E7 might also target the p300 transcriptional coactivator.
Results

HPV-16E7 interacts with p300 in vitro
In order to investigate whether E7 could interact with p300, several overlapping fragments of p300 were expressed as GST fusion proteins ( Figure 1a ) and purified; these recombinant proteins were then incubated with in vitro translated, radiolabelled HPV-16E7. The complexes were washed, separated by SDS-PAGE and analysed by autoradiography. As shown in Figure 1b , HPV-16E7 binds strongly to GST-p300 fragment 1, which encompasses the CH1 domain of p300. Weaker interaction was observed with the CH2 and CH3 domains, while no significant binding was seen with fragments of p300 spanning residues 672-1193 and 1893-2414. To exclude any possible contribution by the N-terminal part of p300 to binding 16E7, we repeated the binding assay using the TAZ domain of p300 (residues 336-430) and the KIX domain (residues 568-646). The results obtained from the pull-down assay can be seen in Figure 1c . No interaction with the KIX domain is seen, while strong binding to the TAZ (CH1 region) domain comparable with the binding to the p300 fragment 1 (1-672) was obtained. These results demonstrate that the major E7-binding site on p300 lies within residues 336-430, encompassing the CH1 domain.
Having found that HPV-16E7 could bind to p300, we then proceeded to investigate the ability of low-risk HPV-11E7 to interact with p300. The GST pull-down assay was performed using full-length GST-11E7 and -16E7 and in vitro translated full-length p300. GST-TBP was used as positive control. As can be seen from Figure 1d , the high-risk 16E7 interacts with p300 with an affinity comparable to its interaction with TBP. Interestingly, the low-risk HPV-11E7 protein is also able to bind to p300, although the interaction is a little weaker than that of the high-risk 16E7.
To determine which residues of HPV-16E7 are required for complex formation with p300, we repeated the binding assays with a number of previously described (Edmonds and Vousden, 1989; Banks et al., 1990; Massimi et al., 1997) mutants of HPV-16E7 ( Figure 2a ). As shown in Figure 2b , all the deletion mutants (D1 : 52-55 aa, D2 : 65-67 aa, D3 : 75-77 aa, D4 : 79-83 aa) within the C-terminal half of HPV-16E7 retained the ability to bind to p300 at levels comparable with the wildtype E7 protein. In contrast, mutants within the aminoterminal domain of E7, p24 (C24G: deficient in pRb binding), CK2 (S31R, S32P: deficient in CKII phosphorylation), as well as p2 (H2P: within N-terminus), showed greatly reduced binding to p300, while the double mutant, CK2-p24, also has reduced binding close to background levels. These results suggest that the Nterminal region of E7 encompassing the H2P mutation as well as the pRb binding and CKII phosphorylation sites are all required for the association with p300.
Since E7 has previously been shown to interact with a variety of cellular proteins, including TBP and P/CAF (Massimi et al., 1996; Huang and McCance, 2002; Avvakumov et al., 2003) , all of which also interact with p300, it was obviously possible that the interaction between E7 and p300 was indirect. To investigate this possibility, we repeated the pull-down assays using purified His-tagged HPV-16E7 and purified GST-p300 fusion fragments. The bound E7 protein was then analysed by Western blotting with an anti-16E7 antibody. As can be seen from Figure 3a , the pattern of the E7-p300 binding is similar to that observed using in vitro translated 16E7, with the main binding site lying within the CH1 domain of p300.
E7 interacts with p300 in vivo
The above studies demonstrate a strong direct interaction between HPV-16 E7 and p300 in vitro. To confirm that this was a physiologically relevant interaction, a series of coimmunoprecipitation assays were performed from cells expressing 16E7 and p300. Firstly, HA-tagged 16E7 was transfected into U2-OS cells, and coimmunoprecipitation assays performed using an anti-p300 antibody. As can be seen from Figure 4a , a significant amount of E7 protein is co-precipitated with the antip300 antibody. The coimmunoprecipitation assay was then repeated on cells expressing endogenous E7 protein: E7-and EJ-ras-transformed BRK cells and cervical tumour-derived CaSki cells. The coimmunoprecipitation was done using either anti-E7 (Santa Cruz ED17) or anti-p300 antibodies (NM11 Pharmingen and Santa Cruz C-20), and the immune complexes were subsequently analysed by Western blot. To avoid the Interaction between the HPV-16E7 oncoprotein and p300. The major site of interaction on p300 lies within fragment 1, which encompasses the CH1 domain; weak interaction is seen with domains encompassing CH2 and CH3. Corresponding GST protein inputs are shown in the bottom panel and the percentage of in vitro translated E7 protein bound to the different fusion proteins is also indicated. (c) Fine mapping of the E7 interaction site on p300. In vitro translated E7 protein was incubated with the different GST fusion proteins and binding assessed following extensive washing, PAGE and autoradiography. The major binding site lies within the TAZ domain, which encompasses the CH1 domain and spans residues 336-430. The lower panel shows the inputs of the GST fusion proteins used in the assay and percentage of in vitro translated E7 protein bound is also shown. (d) Interaction between the low-risk 11E7 and high-risk 16E7 (produced as GST fusion proteins) and full-length in vitro translated p300. GST-TBP was used as positive control. The bottom panel shows the inputs of the GST fusion proteins used and the percentage of in vitro translated p300 bound is also shown HPV E7 interaction with p300 A Bernat et al interference of immunoglobulin light chains which would be expected to migrate just above the E7 protein on SDS-PAGE, all the antibodies were previously crosslinked to protein A or protein G-sepharose resin. Using the E7-transformed BRK cells, it is clear that the anti-p300 antibody coimmunoprecipitated a protein of approximately 18-20 kDa that comigrates with the in vitro translated E7 protein, and just below the E7 species precipitated from the cells with the anti-E7 antibody ( Figure 4b ). Likewise, similar results were obtained when the experiment was performed in CaSki cells (Figure 4c ). Two different anti-p300 antibodies, NM11 (Pharmingen) and C20 (Santa Cruz), coimmunoprecipitated HPV-16E7 from the CaSki cell extracts, although the C20 antibody appeared to be much less efficient (Figure 4c ). In addition, an anti-E7 polyclonal antibody was also able to coimmunoprecipitate a protein from CaSki cells, of approximately 280-300 kDa, which was recognized by the anti-p300 antibody in Western blot ( Figure 4d) .
As a final verification that HPV-16 E7 can interact with p300 in vivo, we performed a series of mammalian two-hybrid assays. HPV-16E7 was fused to the GAL4 DNA-binding domain and cotransfected into CV-1 cells with constructs expressing the CH3 domain of p300 or CBP fused to the VP16 activation domain. After 48 h, the cells were harvested and luciferase activity measured. As can be seen from the results in Figure 4e , E7 interacts specifically with the CH3 domain of p300 and, interestingly, with the equivalent region of CBP. No interaction was observed with the region of CBP spanning residues 1892-2441. These results are in agreement with the mapping studies performed in vitro and, taken together, demonstrate that E7 and p300 are able to form a complex in vivo in E7-transformed BRK cells, mammalian cells transfected with E7 and cells derived from a cervical tumour. protein together with the location of mutants used for the in vitro pull-down assays; p24 (C24G) -mutant deficient in pRb binding; CK2 (S31R, S32P) -mutant deficient in CKII phosphorylation; Cterminal deletion mutants -D1 : 52-55 aa, D2 : 65-67 aa, D3 : 75-77 aa, D4 : 79-83 aa, p24.CKII (double mutant C24G, S31R, S32P) and p2 (H2P). (b) Interaction of the HPV-16E7 mutants (indicated in panel a) and wild-type E7 with GST-p300 fragments #1 and #2. GST-alone was used for negative control. The GST protein inputs are shown at the bottom of the figure and the numbers below each panel show the percentage of input protein bound on the beads Figure 3 The interaction between HPV-16E7 and p300 is direct. Bacterially derived 6-His-tagged 16E7 was incubated with the GSTp300 fusion protein fragments. The bound complexes were removed from glutathione beads, separated on 15% SDSpolyacrylamide gel and blotted with anti-16E7 antibody (Santa Cruz ED17). GST-TBP and GST-alone were used as positive and negative controls, respectively. The percentage of protein bound is indicated, as determined by densitometric scanning. The relative purity of the His 6 -16E7 protein used in the assay is shown in the lower panel, where M are markers, lane 1 is protein bound to the nickel-agarose and lane 2 is the protein eluted for the binding assay
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E7 and p300 colocalize
To confirm the above biochemical data, we next performed a series of experiments to determine whether E7 and p300 localize within the same cellular compartments. To do this, U2-OS cells were either transfected with HA-tagged HPV-16E7 alone and the pattern of expression was compared with endogenous p300, or were transfected with HA-tagged E7 and pCMV : p300. The anti-p300 antibody (NM11 Pharmingen) identified p300 in U2-OS cells in a meshwork pattern of expression throughout the whole nucleoplasm, overlaid with several brighter foci of variable size with dot-like structures ( Figure 5a ). This pattern of staining was more evident when p300 was overexpressed (Figure 5b ) from the exogenous plasmid. In agreement with previous studies (Smith-McCune et al., 1999; Guccione et al., 2002) , HPV-16E7 in U2-OS cells shows predominantly nuclear localization with nucleolar exclusion (Figure 5a, b) . Merged images showed multiple regions and dot-like structures of E7 and p300 colocalization in the case of endogenous p300 (Figure 5a) , and a similar pattern of colocalization is also seen when both proteins are overexpressed (Figure 5b) . The experiment was then repeated using the low-risk, HA-tagged HPV-11E7. As can be seen from Figure 5c , overexpression of both HAtagged HPV-11E7 and p300 showed that low-risk 11E7 also colocalizes with p300 ( Figure 5c ). HA-11E7 shows distinct regions of concentration within the nucleus, with the presence of clear dot-like structures. Very similar patterns of expression have been observed for proteins that localize to PML oncogenic domains (PODs) (Sternsdorf et al., 1997) , including p300/CBP. These results demonstrate that E7 and p300 exist in the same cellular compartments and further support the in vitro and in vivo interaction studies.
HPV-16E7 represses the transcriptional coactivation function of p300
We next wanted to investigate what effect HPV-16E7 might have upon the transcriptional activity of p300. (Massimi et al., 1996) was able to coimmunoprecipitate a protein of approximately 280-300 kDa from CaSKi cells endogenously expressing E7 and p300, which was recognized in Western blot by anti-p300 antibody (NM11 Pharmingen). Controls included as in previous panel. The arrow indicates the position of p300. (e) HPV-16E7 interacts with the CH3 domains of p300 and CBP in mammalian two-hybrid tests. CV-1 cells were cotransfected with the (gal)6-luc reporter plasmid, together with vectors expressing HPV-16E7 fused to the Gal4 DBD and vectors expressing the indicated portions of p300 or CBP fused to a transcriptional activation domain. At 48 h post-transfection, cells were harvested and assayed for luciferase activity. The results show the mean of three independent experiments and standard deviations are also shown b HPV E7 interaction with p300 A Bernat et al Recent reports (Lee et al., 2000; Marcello et al., 2000) have shown a strong synergistic transcriptional activity between the HPV-E2 protein and p300. This is very relevant to the context in which E7 would usually be expressed; therefore, we chose to assess the effects of E7 upon p300 coactivation function. U2-OS cells were transiently transfected with a CAT reporter construct containing six E2-binding sites, together with plasmids expressing E2, p300 and E7. As can be seen in Figure 6a , p300 stimulates E2-dependent transcriptional activity, and this is in agreement with previous studies (Lee et al., 2000; Marcello et al., 2000) .
In contrast, addition of E7 results in a dramatic reduction in the ability of p300 to coactivate E2-driven transcription. In the control experiments, in which the E2 expression plasmid was omitted, the cotransfection of E7 or p300 had no effect on promoter activity (Figure 6b ), nor did cotransfection of E7 and E2. The latter point is not surprising, since E2 associates with a large number of transcription factors and it is not clear what proportion of E2's transcriptional activity is alone dependent upon interaction with the endogenously expressed p300. Having shown that E7 could specifically inhibit the transcriptional coactivation function of p300, we next wished to investigate whether this was a consequence of E7 binding to p300. To do this, we used the 16E7 C24G (p24) mutant, which we had shown to be deficient in Figure 5 HPV-16E7 and p300 colocalize in the nucleus of U2-OS cells. (a) HA-tagged 16E7 (red) transiently transfected into U2-OS cells colocalizes with the endogenous p300 (green). Cells were fixed in 3% PFA, permeabilized with Triton X-100 and stained with anti-HA antibody (Santa Cruz Y-11) and anti-p300 antibody (NM11 Pharmingen). (b) U2-OS cells were transiently transfected with HAtagged 16E7 and CMVb-p300. Cells were fixed in 3% PFA, permeabilized with Triton X-100 and stained with anti-HA (Santa Cruz Y-11) antibody and anti-p300 antibody (NM11 Pharmingen). (c) U2-OS cells were transiently transfected with HA-tagged 11E7 and CMVb-p300. Cells were fixed in 3% PFA, permeabilized with Triton X-100 and stained with anti-HA (Santa Cruz Y-11) antibody and anti-p300 antibody (NM11 Pharmingen)
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A Bernat et al p300 binding. HPV-11E7 and Ad E1a were also included in the assay for comparison. The results are shown in Figure 6b and demonstrate that, while wildtype E7 abolishes p300 transcriptional function, the non-p300-binding mutant p24 is defective in this context. In contrast, the weaker binding 11E7 displayed a reduced ability to abolish p300 activity, while the strongest binding Ad E1a exhibited the most dramatic effect upon p300 coactivation function. These results demonstrate that one consequence of the E7-p300 interaction is suppression of p300 transcriptional coactivation function in the context of the HPV-16E2 transactivator.
Discussion
HPV E7 exerts its oncogenic function at least in part by modulating cellular growth-regulatory pathways. Cell transformation by E7 is mediated by the physical association of E7 with cellular regulatory proteins whose functions are specifically altered by E7, as exemplified by the well-known interaction with the retinoblastoma protein (Dyson et al., 1989) . However, the E7 interaction with pRb represents just one of the many distinct interactions that are relevant for cell transformation. In this study, we demonstrate that the E7 protein derived from both low-and high-risk HPV types is capable of interacting with p300. Given the vital importance of p300 in the control of key biological processes, it is not surprising that it is frequently targeted by viral regulatory proteins. Some of the viral proteins, such as human T-cell leukaemia virus (HTLV-1) Tax and HPV E2, require p300/CBP for their transcriptional activities (Lee et al., 2000; Georges et al., 2002) . Others, such as adenovirus (Ad) E1a and simian virus (SV40) large T antigen, appear to block the normal function of p300 (Jelsma et al., 1989; Peeper and Zantema, 1993) . The demonstration that HPV E7 also binds to p300 and inhibits its transcriptional activity would place it in this latter class of viral proteins. Viral oncoproteins that use p300/CBP as a coactivator seem to do so by interacting with the CREB-binding domain. These viral transactivators must also be capable of binding, either directly or indirectly, to appropriate sites in the gene promoters. Viral oncoproteins that abolish p300/CBP function often do not bind DNA. These proteins tend to interact usually with the third zinc-finger domain, a region that has been shown to mediate interactions with positive effectors of p300/CBP action, such as RNA helicase A, TFIIB and histone acetylase P/CAF. The binding of Ad E1a to p300 causes the inhibition of both its transcriptional coactivator and HAT activities (Arany et al., 1995; Lundblad et al., 1995; Chakravarti et al., 1999; Hamamori et al., 1999) . The regions of E1a required for transcriptional repression (amino acids 1-30 and 48-60) overlap those required for binding p300 in vivo . Both Ad E1a and SV40 LT have also been shown to require interaction with p300 in order to efficiently transform cells (Smith and Ziff, 1988; Stein et al., 1990; Eckner et al., 1996) . In the case of E7, it appears to interact principally with the p300 CH1 domain. However, a weaker interaction is also seen with the CH2 and CH3 domains, and interestingly, binding to the equivalent CH3 domain of CBP was also found in the mammalian two-hybrid analysis, suggesting that CBP may also be a target of E7. Studies are in progress to investigate this further. Several transcription regulators have been shown to interact with p300 within the CH1 finger domain, including TBP , p73 (Zeng et al., 2000) and MDM2 (Grossman et al., 1998) . The complexes of these regulators with p300 could serve as functional targets of the HPV E7 protein in transcriptional regulation, through which E7 might exert its transforming activity. Other viral proteins such Figure 6 (a) HPV-16E7 inhibits the p300 coactivation function. Transcriptional coactivation function of p300 was measured in the context of the HPV-16 E2 protein in transiently transfected U2-OS cells. To measure the transcriptional activity of E2, 1 mg of 6 Â E2CAT, 0.5 mg of pSVb-gal (to standardize E2 activation values for transfection efficiency) along with 1 mg of E2 (pJ4O), 5 mg of CMV-b p300 and 1 or 5 mg of 16E7 (pJ4O) were cotransfected. The total amount of DNA was equalized with empty plasmids. The mean values from three independent experiments are presented. Transfections and CAT assays were performed as described in Materials and methods. (b) Inhibition of p300 coactivation function by E7 and E1a correlates with the strength of interaction. The effect of low-risk HPV-11E7, Ad E1a and the p24 mutant (C24G) on p300-mediated E2-dependent transcription. In all, 5 mg of indicated plasmids was cotransfected HPV E7 interaction with p300 A Bernat et al as Ad E1a, HTLV-1 Tax and HPV E6 have also been shown to interact with multiple p300/CBP sites (Korzus et al., 1998; Kurokawa et al., 1998; Yan et al., 1998; Scoggin et al., 2001; Bernat et al., 2002) , suggesting that different viral regulatory proteins engage similar strategies for interfering with the normal functions of p300.
We also demonstrate that the interaction between 16E7 and p300 is direct, and that p300-16E7 complexes are relatively stable, since they could be extracted from cells in the presence of 300 mm NaCl. The residues of HPV-16E7 involved in binding p300 lie within the Nterminal domain of 16E7. Interestingly, previous studies have shown that an amino-terminal mutant of 16E7 was unable to complement an E1a mutant defective in p300 binding (Davies and Vousden, 1992) , and that E7 can complement the transcription coactivation function of the E1a amino-terminus in the transactivation of viral early promoters (Wong and Ziff, 1996) . These results might be explained, at least partially, by the data presented here. It is also interesting to note that, similar to E1a and SV40 LT (Edmonds and Vousden, 1989; Mymryk, 1998) , the regions of E7 required for binding p300 overlap with the pRb-binding domain. This raises the possibility that E7s interactions with p300 and pRb are mutually exclusive events and this requires further investigation. It is also worth noting that the form of E7 coimmunoprecipitating with p300 from cells endogenously expressing both proteins had a molecular weight slightly smaller than the major E7 species found in these cells, and instead comigrated with E7 obtained from in vitro translations. This suggests that the form of E7 preferentially binding to p300 may be an unmodified form of the protein. Since the CKII phosphorylation site is also required for the interaction, this raises the possibility that phosphorylation may be a means of regulating the E7-p300 association.
Recent studies have demonstrated that HPV-16E6 and bovine papillomavirus type 1 (BPV-1) E6 can also interact with the p300/CBP coactivator protein (Patel et al., 1999; Zimmermann et al., 1999 Zimmermann et al., , 2000 Bernat et al., 2002) . As a result of this interaction, the transcriptional activity of p300 is greatly reduced, suggesting that E6 can interfere with the normal function of p300 (Patel et al., 1999; Zimmermann et al., 1999) . Moreover, it has been demonstrated that the E6-p300 interaction may contribute to E6-induced cell transformation ). Here we demonstrate that another HPV oncoprotein also interacts with the same cellular target. Such a phenomenon is not a rare event among viral transforming proteins. An example of this is the adenovirus E4orf6 and E1B55K proteins, both interacting directly with the p53 tumour suppressor (Querido et al., 2001) .
The HPV E2 protein has also been shown to interact with p300/CBP (Lee et al., 2000; Marcello et al., 2000) . E2 protein can function as transcriptional repressor or activator, depending upon the levels of E2 expression (Choe et al., 1989; Bouvard et al., 1994; Stubenrauch et al., 1998) . Loss of E2 is also believed to be an important step in the development of cervical cancer, since in the majority of tumours, the viral DNA is integrated into the host genome and the E2 gene is disrupted. E2 interacts with the CBP KIX domain, which is required for stable interaction with CREB (Kwok et al., 1994) , and this interaction appears to enhance the ability of E2 to activate viral gene expression. This interaction may also play a role in the differentiation-dependent activation of viral gene expression, since recent studies have shown that the level of p300 expression increases during keratinocyte differentiation (Mu¨ller et al., 2002) . It is therefore intriguing that the interaction between E7 and p300 results in abrogation of E2-p300 coactivator function. This suggests that E7-p300 interaction may represent a means of fine-tuning the levels of viral oncoprotein expression during viral infection. However, during virus-induced malignancy, it seems likely that the indirect consequence of the E7-p300 interaction will be inhibition of p300 function, and hence may be a direct contribution towards virus induced cell transformation.
Materials and methods
GST fusion protein expression and purification
GST-p300 fusion proteins were kindly provided by S Hasan. GST-16E7 and GST-p53 have been described previously (Massimi et al., 1996) . GST-TAZp300 and GST-KIXp300 were generating by cloning into pGEX-2T (BamHI/EcoRI) PCR products obtained by amplification with following primers: TAZ: Forward: TAATAAGGATCCCCAGAGAAGCGC-AAG Reverse:
TAATAAGAATTCACTCAAAATTGGC-TG KIX: Forward: TAATAAAGATCTCGGAAACAGTGG-CAC Reverse: TAATAAGAATTCACTTTCTTCTAGT-TCTTTCTC Constructs were then verified by DNA sequencing. For protein production and purification, 50 ml of an overnight culture of E. coli strain BL-21 previously transformed with the appropriate expression plasmids were diluted 1 : 10 in Luria Broth containing ampicillin, and grown at 371C up to an OD of 0.6. Recombinant protein expression was induced for 3 h with 1 mm isopropyl-b-d-thiogalactopyranoside (IPTG, Sigma). The cells were harvested by centrifugation, disrupted by sonication in lysis buffer (20 mm Tris-HCl pH 7.5, 250 mm NaCl, 0.5% NP40, 2 mg/ml aprotinin, 100 mm TPCK and 50 mm TLCK), and the lysates were then cleared from cell debris by centrifugation at 13 000 r.p.m. The GST-fusion proteins were then incubated for 1 h with glutathione-conjugated agarose beads (Sigma) and bound proteins were washed extensively with lysis buffer. The levels and purity of proteins were determined by SDS-PAGE and Coomassie Brilliant Blue R staining.
Cells and transfections
U2-OS (human osteosarcoma), CaSki (human cervical epidermoid carcinoma HPV16 positive), baby rat kidney (BRK) and CV-1 (monkey kidney) cells were grown in DMEM supplemented with 10% foetal bovine serum, 2 mm lglutamine, 100 U/ml penicillin and 100 mm streptomycin at 371C and 10% CO 2 . Unless otherwise stated, transfections were done using standard calcium phosphate precipitation (Wigler et al., 1979) . The BRK cell line expressing 16E7 was obtained by transfecting primary BRK cells from 9-day-old Wistar rats with EJ-ras (pEJ6.6) plus HA-16E7 in pcDNA3. After 2 weeks under G418 selection (100 mg/ml), single transformed colonies were picked and expanded.
Mammalian two-hybrid assay
The HPV16 E7 gene was expressed as a fusion to GAL4p DNA-binding domain in the vector pM, while the indicated portions of p300 or CBP were expressed as fusions to the VP16 activation domain in vector pVP16 (Clontech). The (gal) 6 -luc reporter plasmid contains a luciferase gene immediately downstream of six repeats of the GAL4p-binding region and a minimal TATA box, and was generously provided by Dr J Torchia. CV-1 cells were transfected using Effectene transfection reagent (Qiagen Inc.) according to the manufacturer's instructions. Luciferase assays were performed 48 h posttransfection.
Chloramphenicol acetyltransferase (CAT) reporter assay
To measure the cotranscriptional activity of E2 and p300, cells were transfected with 1 mg of 6 Â E2CAT, 0.5 mg of pSVb-gal (to standardize E2 activation values for transfection efficiency) plus 1 mg of pJ4O.16E2, 5 mg of CMV-bp300 and either 1 or 5 mg of pJ4O.16E7 or 5 mg of pJ4O.11E7, or 5 mg pJ4O.p24 or 5 mg pCE.E1a as indicated in the text. The total amount of DNA was equalized with empty plasmids. Cells were harvested after 48 h, lysed (40 mm Tris-HCl pH 7.5, 150 mm NaCl, 1 mm EDTA) and subjected to three cycles of freezing and thawing. CAT assays were carried out as described previously .
GST pull-down assays and constructs
Equal amounts of GST fusion proteins bound to glutathionelinked agarose beads were incubated for 1 h at room temperature with in vitro translated radiolabelled protein, produced using the TNT reticulocyte lysate system (Promega). The reaction was carried out in a final volume of 50 ml, in a binding buffer containing 50 mm Tris-HCl pH 7.5, 150 mm NaCl and 2.5 mm EDTA. The bound proteins were washed extensively in PBS/0.5%NP40. SDS-PAGE and autoradiography were used to analyse the pattern of bound proteins.
A number of previously described mutants of HPV-16E7 were used: the deletion mutants D1 : 52-55 aa, D2 : 65-67 aa, D3 : 75-77 aa, D4 : 79-83 aa within the C-terminal half of HPV-16E7 (Massimi et al., 1996) ; mutants within the CR2 domain of E7 (Edmonds and Vousden, 1989) ; p24 (C24G, deficient in pRb binding) and CK2 (S31R, S32P, mutant deficient in CKII phosphorylation) as well as p2 (H2P). The CKII mutant subcloned into pcDNA3-HA (BamHI/ EcoRI) was used as a substrate for p24 mutagenesis (C24G) using the Gene Tailor TM Site-Directed Mutagenesis System (Invitrogen) to generate the double mutant p24-CKII (C24G, S31R, S32P). This was done using the following pair of primers:
Forward: CAGAGACAACTGATCTCTCTAACGGATA-TGAGCAAT Reverse:
GTAGAGATCAGTTGTCTCTGGTTGCAAA-TC The resulting double mutant was then verified by DNA sequencing.
Western blotting and coimmunoprecipitation
For coimmunoprecipitations, cells were rinsed in ice-cold PBS and lysed on ice in buffer B (50 mm Tris-HCl pH 7.5, 150 mm NaCl, 0.5% NP40, 5% glycerol, 100 mm TPCK, 50 mm TLCK). Lysates were cleared by centrifugation at 13 000 r.p.m. for 10 min, incubated with the appropriate specific antibodies (specified in the text) for times ranging from 1 h to overnight at 41C, and subsequently mixed with either protein A or protein G agarose beads (Amersham Pharmacia Biotech.) for 40 min. Where necessary, antibodies were covalently bound to the protein A or protein G using 5 mg/ml dimethylpimelimidate (Pierce) as crosslinker.
For Western blotting, cellular extracts were prepared as described above. Protein concentrations were determined using the Bio-Rad Protein Assay System. Equal amounts of cell extract were then separated on SDS-PAGE and transferred to nitrocellulose membrane. Proteins were detected with the appropriate specific antibodies (anti-p300 NM11 Pharmingen, anti-16E7 Santa Cruz ED17), and developed with the Amersham ECL System according to the manufacturer's instructions.
Immunofluorescence and confocal microscopy
At 24 h after transfections, cells were washed in PBS and fixed with 3% PFA for 15 min at room temperature. After further washing, the cells were permeabilized with 1% Triton for 5 min and then washed extensively with PBS. Endogenous and overexpressed p300 was visualized using an anti-p300 monoclonal antibody (NM11 Pharmingen) diluted 1 : 100 in PBS. HA-tagged E7 was visualized using a rabbit anti-HA antibody (Santa Cruz Y-11) diluted 1 : 200 in PBS. After 1 h incubation at 371C and extensive PBS washing, secondary antibodies (rhodamine-conjugated goat anti-rabbit and fluorescein-conjugated goat anti-mouse), both diluted 1 : 1000 were added. The cells were incubated at 371C for 20 min and then washed extensively, first with PBS and then with water, and finally mounted on glass microscope slides using Vectashield mounting medium (Vector Labs Inc.). A Zeiss Axiovert 100M microscope with Â 100 objective oil-immersion lens was used for confocal laser-scanning microscopy. An LSM 510 confocal unit with two lasers giving excitation lines at 543 and 488 nm was attached. Data were collected at 1024 Â 1024-pixel resolution. Scanning conditions were kept constant in each experiment to ensure that the signal overlap between channels was essentially eliminated.
